Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.

To identify molecularly defined subgroups in multiple myeloma, gene expression profiling was performed on purified CD138(+) plasma cells of 320 newly diagnosed myeloma patients included in the Dutch-Belgian/German HOVON-65/GMMG-HD4 trial. Hierarchical clustering identified 10 subgroups; 6 corresponded to clusters described in the University of Arkansas for Medical Science (UAMS) classification, CD-1 (n = 13, 4.1%), CD-2 (n = 34, 1.6%), MF (n = 32, 1.0%), MS (n = 33, 1.3%), proliferation-associated genes (n = 15, 4.7%), and hyperdiploid (n = 77, 24.1%). Moreover, the UAMS low percentage of bone disease cluster was identified as a subcluster of the MF cluster (n = 15, 4.7%). One subgroup (n = 39, 12.2%) showed a myeloid signature. Three novel subgroups were defined, including a subgroup of 37 patients (11.6%) characterized by high expression of genes involved in the nuclear factor kappa light-chain-enhancer of activated B cells pathway, which include TNFAIP3 and CD40. Another subgroup of 22 patients (6.9%) was characterized by distinct overexpression of cancer testis antigens without overexpression of proliferation genes. The third novel cluster of 9 patients (2.8%) showed up-regulation of protein tyrosine phosphatases PRL-3 and PTPRZ1 as well as SOCS3. To conclude, in addition to 7 clusters described in the UAMS classification, we identified 3 novel subsets of multiple myeloma that may represent unique diagnostic entities.

[1]  V. Pantesco,et al.  Gene expression of anti‐ and pro‐apoptotic proteins in malignant and normal plasma cells , 2009, British journal of haematology.

[2]  Axel Benner,et al.  Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. , 2008, Blood.

[3]  M. Kersten,et al.  First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM) , 2008 .

[4]  H. Kazazian,et al.  Induction of Immune Tolerance to Canine FVIII in Hemophilia a Dogs with Inhibitors Using AAV-Mediated Expression of Canine FVIII , 2008 .

[5]  Laurence Lodé,et al.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Ahmet Dogan,et al.  The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. , 2008, Blood.

[7]  F. Zhan,et al.  Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. , 2008, Blood.

[8]  G. Donofrio,et al.  Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. , 2007, Cancer research.

[9]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[10]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[11]  Rafael Fonseca,et al.  Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. , 2007, Cancer research.

[12]  P. Raynaud,et al.  Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis1 , 2007, The Journal of Immunology.

[13]  Anthony Boral,et al.  Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.

[14]  T. Rème,et al.  CD200 is a new prognostic factor in multiple myeloma. , 2006, Blood.

[15]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[16]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[17]  G. Ahmann,et al.  Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations , 2006, Leukemia.

[18]  D. Hose,et al.  Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics , 2005, Genes, chromosomes & cancer.

[19]  G. Ahmann,et al.  A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. , 2005, Blood.

[20]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Bart Barlogie,et al.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.

[22]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[23]  Lin-Feng Chen,et al.  NF-κB Is Essential for Induction of CYLD, the Negative Regulator of NF-κB , 2004, Journal of Biological Chemistry.

[24]  F. Zhan,et al.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. , 2003, The New England journal of medicine.

[25]  J. Soulier,et al.  Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases , 2003, Genes, chromosomes & cancer.

[26]  R. Fonseca,et al.  The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. , 2003, Blood.

[27]  R. Bataille,et al.  CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. , 2003, Blood.

[28]  Tony Reiman,et al.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.

[29]  J. Baars,et al.  Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. , 2002, Blood.

[30]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C. Bastard,et al.  Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.

[32]  Christian A. Rees,et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Hunter,et al.  Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signaling , 1995, Cell.

[34]  Hong Sun,et al.  The coordinated action of protein tyrosine phosphatases and kinases in cell signaling. , 1994, Trends in biochemical sciences.

[35]  H. Clevers,et al.  Identification of primary MAFB target genes in multiple myeloma. , 2009, Experimental hematology.

[36]  S. Bicciato,et al.  Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. , 2007, Haematologica.

[37]  J. V. van Dongen,et al.  Two dual-color split signal fluorescence in situ hybridization assays to detect t(5;14) involving HOX11L2 or CSX in T-cell acute lymphoblastic leukemia. , 2004, Haematologica.

[38]  Lin-Feng Chen,et al.  NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. , 2004, The Journal of biological chemistry.

[39]  T. Otsuki,et al.  Upregulated production of IL-6, but not IL-10, by interferon-alpha induces SOCS3 expression and attenuates STAT1 phosphorylation in myeloma cells. , 2004, The hematology journal : the official journal of the European Haematology Association.

[40]  G. Ahmann,et al.  Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. , 1999, Leukemia & lymphoma.

[41]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[42]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.

[43]  B. Zhivotovsky,et al.  Interferon (cid:1) -induced Apoptosis in Tumor Cells Is Mediated through the Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Signaling Pathway* , 2022 .